Plerixafor-d4
(Synonyms: 普乐沙福 d4) 目录号 : GC47963An internal standard for the quantification of plerixafor
Cas No.:1246819-87-3
Sample solution is provided at 25 µL, 10mM.
Plerixafor-d4 is intended for use as an internal standard for the quantification of plerixafor by GC- or LC-MS. Plerixafor is a partial antagonist of chemokine receptor 4 (CXCR4) with IC50 values ranging from 0.02 to 0.13 µg/ml for inhibiting calcium flux in peripheral blood mononuclear cells (PBMCs), various types of T cells, and mouse lymphocytic leukemia cells.1 It is selective for CXCR4 over CXCR1-3 and CXCR5-9 (IC50s = >25 µg/ml). Plerixafor decreases infectious virus content in the supernatant of Jurkat cells chronically infected with HIV-1(IIIB) (EC50 = ~0.02 µg/ml).2 It rapidly mobilizes murine and human hematopoietic stem and murine long-term repopulating cells for transplantation alone and, with a synergistic effect, when used in combination with G-CSF.3 Plerixafor also increases T cell trafficking in mouse blood, spleen, and central nervous system.4,5 Plerixafor (1.25 mg/kg twice per day) decreases the number of 4T1 murine mammary carcinoma cells in the lung in a mouse model of lung metastasis.6
1.Hatse, S., Princen, K., Bridger, G., et al.Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4FEBS Lett.527(1-3)255-262(2002) 2.De Clercq, E., Yamamoto, N., Pauwels, R., et al.Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100Antimicrob. Agents Chemother.38(4)668-674(1994) 3.Hess, D.A., Bonde, J., Craft, T.C., et al.Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factorBiol. Blood Marrow Transplant13(4)398-411(2007) 4.Bernardini, G., SciumÈ, G., Bosisio, D., et al.CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsetsBlood111(7)3626-3634(2008) 5.McCandless, E.E., Zhang, B., Diamond, M.S., et al.CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from west nile virus encephalitisProc. Natl. Acad. Sci. U.S.A.105(32)11270-11275(2008) 6.Smith, M.C., Luker, K.E., Garbow, J.R., et al.CXCR4 regulates growth of both primary and metastatic breast cancerCancer Res.64(23)8604-8612(2004)
Cas No. | 1246819-87-3 | SDF | |
别名 | 普乐沙福 d4 | ||
Canonical SMILES | [2H]C1=C([2H])C(CN2CCCNCCNCCCNCC2)=C([2H])C([2H])=C1CN3CCCNCCNCCCNCC3 | ||
分子式 | C28H50D4N8 | 分子量 | 506.8 |
溶解度 | Methanol: slightly soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9732 mL | 9.8658 mL | 19.7316 mL |
5 mM | 0.3946 mL | 1.9732 mL | 3.9463 mL |
10 mM | 0.1973 mL | 0.9866 mL | 1.9732 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet